Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Octreotide.

× No keyword cloud information.

224 in total

1. Molecular Events as Targets of Anticancer Drug Therapy.

Authors: Adorján Aszalós; Sándor Eckhardt
Journal: Pathol Oncol Res Date: 1997 Impact factor: 3.201

Review 2. The therapeutic value of somatostatin and its analogues.

Authors: S Farooqi; J S Bevan; M C Sheppard; J A Wass
Journal: Pituitary Date: 1999-06 Impact factor: 4.107

Review 3. Autonomic dysfunction of the beta-cell and the pathogenesis of obesity.

Authors: Robert H Lustig
Journal: Rev Endocr Metab Disord Date: 2003-03 Impact factor: 6.514

4. Reversible blocking of amino groups of octreotide for the inhibition of formation of acylated peptide impurities in poly(lactide-co-glycolide) delivery systems.

Authors: Jae Hwa Ahn; Eun Ji Park; Hye Suk Lee; Kang Choon Lee; Dong Hee Na
Journal: AAPS PharmSciTech Date: 2011-09-21 Impact factor: 3.246

Review 5. Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors: Wouter W de Herder; Steven W J Lamberts
Journal: Endocrine Date: 2003-04 Impact factor: 3.633

Review 6. Is presurgical treatment with somatostatin analogs necessary in acromegalic patients?

Authors: M Losa; P Mortini; M Giovanelli
Journal: J Endocrinol Invest Date: 1999-12 Impact factor: 4.256

Review 7. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Authors: Lisa Bodei; Marta Cremonesi; Chiara Grana; Paola Rocca; Mirco Bartolomei; Marco Chinol; Giovanni Paganelli
Journal: Eur J Nucl Med Mol Imaging Date: 2004-05-19 Impact factor: 9.236

Review 8. Pathophysiology of portal hypertension and its clinical links.

Authors: Yeon Seok Seo; Vijay H Shah
Journal: J Clin Exp Hepatol Date: 2011-11-09

Review 9. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.

Authors: Mauro Cives; Jonathan Strosberg
Journal: Drugs Date: 2015-05 Impact factor: 9.546

10. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.

Authors: E Ghigo; B M K Biller; A Colao; I A Kourides; N Rajicic; R K Hutson; L De Marinis; A Klibanski
Journal: J Endocrinol Invest Date: 2009-12-04 Impact factor: 4.256